Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy

[1]  G. Byrne.  Is there anything to worry about? , 2017, Australasian journal on ageing.

[2]  A. Gill,et al.  BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer , 2016, World Journal of Surgery.

[3]  A. Erika,et al.  Biochemical persistence in thyroid cancer: is there anything to worry about? , 2014, Endocrine.

[4]  R. Tuttle.  Optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation? , 2014, Endocrine.

[5]  A. Miyauchi,et al.  BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients? , 2014, World Journal of Surgery.

[6]  T. Fahey,et al.  Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. , 2013, The Journal of clinical endocrinology and metabolism.

[7]  P. Ladenson,et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.

[8]  L. Le,et al.  BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. , 2012, Surgery.

[9]  A. von Deimling,et al.  Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. , 2012, Endocrine-related cancer.

[10]  J. Bishop,et al.  BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment: A Systematic Review and Meta-Analysis , 2012, Medicine.

[11]  R. Tuttle,et al.  Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[12]  R. Tuttle,et al.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.

[13]  G. Cevenini,et al.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.

[14]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[15]  R. Tuttle,et al.  Contemporary post surgical management of differentiated thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[17]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[18]  E. Baudin,et al.  Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[20]  Tae Yong Kim,et al.  Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. , 2014, European journal of endocrinology.